

ELISpot

Human IL-12/IL-23 p40

Catalog Number EL309

For the quantitative determination of the frequency of cells releasing human IL-12/IL-23 p40.

This package insert must be read in its entirety before using this product.

**FOR RESEARCH USE ONLY.
NOT FOR USE IN HUMANS.**

TABLE OF CONTENTS

Contents	Page
INTRODUCTION	2
PRINCIPLE OF THE ASSAY	3
LIMITATIONS OF THE PROCEDURE	3
PRECAUTIONS.	3
ELISpot SCHEMATIC	4
MATERIALS PROVIDED	5
STORAGE	5
OTHER SUPPLIES REQUIRED	5
TECHNICAL HINTS	6
REAGENT PREPARATION.	6
SAMPLE PREPARATION	7
ASSAY PROCEDURE	7
CALCULATION OF RESULTS	8
REPRODUCIBILITY DATA	8
TROUBLESHOOTING GUIDE	9
REFERENCES	10
ASSAY RECORD TEMPLATE	11

MANUFACTURED AND DISTRIBUTED BY:

R&D Systems, Inc.	TELEPHONE:	(800) 343-7475
614 McKinley Place NE		(612) 379-2956
Minneapolis, MN 55413	FAX:	(612) 656-4400
United States of America	E-MAIL:	info@RnDSystems.com

DISTRIBUTED BY:

R&D Systems Europe, Ltd.	TELEPHONE:	+44 (0)1235 529449
19 Barton Lane		
Abingdon Science Park	FAX:	+44 (0)1235 533420
Abingdon, OX14 3NB	E-MAIL:	info@RnDSystems.co.uk
United Kingdom		

R&D Systems China Co. Ltd.	TELEPHONE:	+86 (21) 52380373
24A1 Hua Min Empire Plaza		
726 West Yan An Road	FAX:	+86 (21) 52371001
Shanghai PRC 200050	E-MAIL:	info@RnDSystemsChina.com.cn

INTRODUCTION

Interleukin 12 (IL-12; also known as NKSF) is a 70 - 75 kDa heterodimeric glycoprotein that belongs to the IL-12 family of heterodimeric cytokines (1-3). It consists of two disulfide-linked subunits which are 35 kDa (p35) and 40 kDa (p40) in size and share no meaningful amino acid (aa) sequence identity with each other (1, 4, 5). The mature p35 subunit is 197 aa in length and contains seven cysteines plus one potential N-linked glycosylation site (1-6). Mature human p35 shares 58% aa identity with mouse and rat p35 (2, 7-9). Mature human p40 is 306 aa in length, with 11 cysteines and three potential N-linked glycosylation sites, and it shares 66% aa identity with mouse and rat p40, respectively (1, 7, 10). While p35 resembles a hematopoietin ligand, p40 strongly resembles the N-terminus of a hematopoietin receptor, exhibiting a WSxWS motif, an immunoglobulin-like domain, and four conserved cysteines (1). This suggests that IL-12 may be a cytokine-receptor analog to the IL-6/soluble IL-6 R complex (4, 6). Notably, while p40 may circulate as either a monomer or homodimer, p35 is never found by itself (3). p40 does, however, serve as the larger of two subunits that comprise IL-23 (3, 11). Finally, while IL-12 is classically thought of as a secreted molecule, membrane-bound IL-12 has been reported on both human and mouse cells (12). Cells known to produce IL-12 include macrophages and dendritic cells (13), monocytes (14), Langerhans cells (15), neutrophils (16), keratinocytes (17), plasmacytoid dendritic cells (18), microglia (5), CD8⁺ DC (mouse cells only) (19), and non-germinal center (CD38⁺CD44⁺) B cells (human cells only) (3, 20).

The high affinity receptor for human IL-12 is composed of at least two type I transmembrane glycoproteins that resemble members of the cytokine receptor superfamily. The first subunit (Rb1) is 100 kDa in size and binds IL-12 with a K_d = 1 nM (21). This receptor serves as the principal binding site for the p40 subunit (4, 5). The second subunit (Rb2) is 130 kDa in size and shows no meaningful aa sequence identity to the Rb1 subunit (5, 21, 22). This receptor appears to be the principal signal transduction component and is suggested to serve as an attachment point for a disulfide-linked p35-p40 heterodimer (4, 5, 22). As noted above, human p40 will circulate either as a monomer, homodimer, or in a complex bound to either p35, forming IL-12, or to p19, forming IL-23 (3-5, 11). Both the homodimeric p40, and IL-23 can bind to the IL-12 R, serving as nonsignaling antagonists (3, 23, 24). Alternatively, the p40 homodimer may also bind to Rb1, activating microglia and macrophages (4, 25).

Functionally, IL-12 has been shown to both enhance cytotoxic activity and induce interferon-gamma (IFN- γ) production in NK cells, T cells and dendritic epidermal T cells (3, 26-28). IL-12 has also been reported to induce IFN- γ production in macrophages (29). IL-12, in conjunction with the other IL-12 family members IL-23 and IL-27, promotes the development of a CD4⁺ Th1 immune response (4, 5, 30). In response to infection, IL-27 is released initially, promoting a Th0 to Th0/1 transition. IL-12 production follows, generating Th1 effector cells. In combination with IL-18, IL-12 creates Th1 memory cells out of effector cells, and these cells are later activated by IL-23 (4).

The Human IL-12/IL-23 p40 ELISpot assay is designed for the detection of IL-12/IL-23 p40 secreting cells at the single cell level, and it can be used to quantitate the frequency of human IL-12/IL-23 p40 secreting cells. ELISpot assays are well suited for monitoring immune responses to various stimuli, treatments and therapies, and they have been used for the quantitation of antigen-specific CD4 and/or CD8 T cell responses. Other methods for the assessment of antigen-specific T cell responses, such as the chromium release assay with quantitation by limiting dilution, are tedious, and require previous *in vitro* expansion of T cells for several days. These assays typically are not suitable for measuring infrequent T cell responses that occur at less than 1 in 1000. ELISpot assays are highly reproducible and sensitive and can be used to measure responses with frequencies well below 1 in 100,000. ELISpot assays do not require prior *in vitro* expansion of T cells, and they are suitable for high-throughput analysis using only small volumes of primary cells. As such, ELISpot assays are useful tools for research in areas as diverse as antigen recognition, vaccine development, and the monitoring of various clinical trials.

PRINCIPLE OF THE ASSAY

The enzyme-linked immunospot (ELISpot) assay was originally developed for the detection of individual B cells secreting antigen-specific antibodies (31, 32). This method has since been adapted for the detection of individual cells secreting specific cytokines or other antigens (33, 34). ELISpot assays employ the quantitative sandwich enzyme-linked immunosorbent assay (ELISA) technique. A monoclonal antibody specific for human IL-12/IL-23 p40 has been pre-coated onto a PVDF (polyvinylidene difluoride)-backed microplate. Appropriately stimulated cells are pipetted into the wells and the microplate is placed into a humidified 37° C CO₂ incubator for a specified period of time. During this incubation period, the immobilized antibody in the immediate vicinity of the secreting cells bind secreted IL-12/IL-23 p40. After washing away any cells and unbound substances, a biotinylated polyclonal antibody specific for human IL-12/IL-23 p40 is added to the wells. Following a wash to remove any unbound biotinylated antibody, alkaline-phosphatase conjugated to streptavidin is added. Unbound enzyme is subsequently removed by washing and a substrate solution (BCIP/NBT) is added. A blue-black colored precipitate forms and appears as spots at the sites of cytokine localization, with each individual spot representing an individual IL-12/IL-23 p40 secreting cell. The spots can be counted with an automated ELISpot reader system or manually using a stereomicroscope.

LIMITATIONS OF THE PROCEDURE

- FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.
- The kit should not be used beyond the expiration date on the kit label.
- Any variation in pipetting and washing techniques, incubation time or temperature, or kit age can cause variation in density of spots, intensity of specific staining and background levels.

PRECAUTIONS



BCIP/NBT is toxic if swallowed, in contact with skin, or if inhaled. It is a highly flammable liquid and vapor may cause serious irritation and damage to organs. Wash hands thoroughly after handling. Do not eat, drink, or smoke when using this product. Wear protective gloves, protective clothing, eye protection, and face protection. Do not breathe fumes. Use only in a well-ventilated area. Keep away from heat, sparks, open flames, and hot surfaces. Keep the container tightly closed.

Some components of this kit contain sodium azide, which may react with lead and copper plumbing to form explosive metallic azides. Flush with large volumes of water during disposal.


Do not use reagents from this kit with components from other R&D Systems' ELISpot or ELISA kits and/or components manufactured by other vendors.

Do not remove the flexible plastic underdrain on the bottom of the microplate before or during incubation and development since it may damage the PVDF membrane filters. The underdrain cover may be removed only after completing the incubation with BCIP/NBT chromogen.


ELISpot SCHEMATIC




Incubate IL-12/IL-23 p40-secreting cells in an antibody-coated well.




Remove cells by washing. Secreted IL-12/IL-23 p40 is captured by the immobilized antibody.



Incubate with biotinylated anti-IL-12/IL-23 p40 antibody.



Incubate with alkaline phosphatase conjugated streptavidin.



Add substrate and monitor the formation of colored spots.

MATERIALS PROVIDED

Human IL-12/IL-23 p40 Microplate (Part 894382) - One 96-well PVDF-backed microplate coated with a monoclonal antibody specific for human IL-12/IL-23 p40.

Detection Antibody Concentrate (Part 894383) - 150 μ L of a 120-fold concentrated solution of a biotinylated polyclonal antibody specific for human IL-12/IL-23 p40 with preservatives.

Streptavidin-AP Concentrate A (Part 895358) - 150 μ L of a 120-fold concentrated solution of Streptavidin conjugated to Alkaline Phosphatase with preservatives.

Dilution Buffer 1 (Part 895307) - 12 mL of a buffer for diluting Detection Antibody Concentrate with preservatives.

Dilution Buffer 2 (Part 895354) - 12 mL of a buffer for diluting Streptavidin-AP Concentrate A with preservatives.

Wash Buffer Concentrate (Part 895308) - 50 mL of a 10-fold concentrated solution of a buffered surfactant with preservative.

BCIP/NBT Chromogen (Part 895867) - 12 mL of a stabilized mixture of 5-Bromo-4-Chloro-3' Indolylphosphate p-Toluidine Salt (BCIP) and Nitro Blue Tetrazolium Chloride (NBT).

Human IL-12/IL-23 p40 Positive Control (Part 894385) - 1 vial (4 ng) of recombinant human IL-12/IL-23 p40; lyophilized.

STORAGE

Store the unopened kit at 2 - 8° C. Do not use beyond the kit expiration date. This kit is validated for single use only. Results obtained with opened/reconstituted reagents at a later date may not be reliable.

OTHER SUPPLIES REQUIRED

- Pipettes and pipette tips
- Deionized or distilled water
- Multi-channel pipette, squirt bottle, manifold dispenser, or automated microplate washer
- 500 mL graduated cylinder
- 37° C CO₂ incubator
- Sterile culture media
- Dissection microscope or an automated ELISpot reader

TECHNICAL HINTS

- To minimize edge effect, place the microplate (bottom down) onto a piece of soft aluminum foil (about 4 x 6 inches). Add cells, cover the microplate with the lid and shape the foil around the edges of the microplate. The foil may be left on the microplate for the rest of the experimental procedure and removed after the color substrate BCIP/NBT has been washed off.
- Do not touch PVDF membrane filters with pipette tips when pipetting cells and reagents to avoid damage to the membrane.
- After completion of the experiment, do not dry the microplate at a temperature higher than 37° C since it may cause cracking of the PVDF membrane filters.
- The 96-well microplate provided in the kit is not sterile. However, due to the short incubation period and presence of antibiotics in the culture media, microbial contamination has not been a problem during the ELISpot procedure.
- The kit is designed for single use only. The layout of the assay should be carefully planned to maximize the use of the plate and reagents provided.
- The controls listed are recommended for each ELISpot experiment.

Positive Control - Use recombinant human IL-12/IL-23 p40 (provided).

Unstimulated/Negative Control - Use the same number of unstimulated cells as stimulated cells.

Background Control - Use sterile culture media.

Detection Antibody Control - Substitute phosphate buffered saline for Detection Antibody.

REAGENT PREPARATION

Wash Buffer - If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. To prepare Wash Buffer, add 50 mL of Wash Buffer Concentrate to 450 mL of deionized water and mix well.

Human IL-12/IL-23 p40 Positive Control - Reconstitute with 250 µL of culture medium that is used to incubate cells.

Detection Antibody - Tap or vortex the vial to release reagent collected in the cap. Transfer 100 µL of Detection Antibody Concentrate into the vial labeled Dilution Buffer 1 and mix well.

For optimal performance, prepare Detection Antibody immediately before use.

Streptavidin-AP - Tap or vortex the vial to release reagent collected in the cap. Transfer 100 µL of Streptavidin-AP Concentrate A into the vial labeled Dilution Buffer 2 and mix well.

For optimal performance, prepare Streptavidin-AP immediately before use.

SAMPLE PREPARATION

The types of effector and responder cells used, method of cell separation, mode of stimulation, and length of incubation are to be determined by each investigator. R&D Systems' cell selection products may be suitable for the purification of effector and responder cells. For a complete product listing of human, mouse, and rat cell selection products, see the R&D Systems' catalog or visit the website at www.RnDSystems.com.

ASSAY PROCEDURE

Bring all reagents as needed to room temperature, except the Detection Antibody Concentrate and Dilution Buffer 1, which should remain at 2 - 8° C. All samples and controls should be assayed at least in duplicate. An Assay Record Template is provided at the back of this insert to record controls and samples assayed.

1. Fill all wells in the microplate with 200 μ L of sterile culture media and incubate for approximately 20 minutes at room temperature.
2. When cells are ready to be plated, aspirate the culture media from the wells. Immediately add 100 μ L of the appropriate cells and controls to each well (see Technical Hints for appropriate controls).
3. Incubate cells in a humidified 37° C CO₂ incubator. Optimal incubation time for each stimuli should be determined by each investigator. **Do not disturb the cells during the incubation period.**
4. Aspirate each well and wash, repeating the process three times for a total of four washes. Wash by filling each well with Wash Buffer (250 - 300 μ L) using a squirt bottle, multi-channel pipette, manifold dispenser, or autowasher. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
Note: Adjust the height of the prongs of the manifold dispenser or autowasher to prevent damage to the membranes.
5. Add 100 μ L of diluted Detection Antibody into each well and incubate at 2 - 8° C overnight.
6. Repeat the wash as in step 4.
7. Add 100 μ L of diluted Streptavidin-AP into each well and incubate for 2 hours at room temperature.
8. Repeat the wash as in step 4.
9. Add 100 μ L of BCIP/NBT Chromogen into each well and incubate for 1 hour at room temperature. **Protect from light.**
10. Discard the chromogen solution from the microplate and rinse the microplate with deionized water. Invert the microplate and tap to remove excess water. Remove the flexible plastic underdrain from the bottom of the microplate, wipe the bottom of the plate thoroughly with paper towels and dry completely either at room temperature (60 - 90 minutes) or 37° C (15 - 30 minutes).

CALCULATION OF RESULTS

The developed microplate can be analyzed by counting spots either manually using a dissection microscope or by using a specialized automated ELISpot reader. Specific spots are round and have a dark center with slightly fuzzy edges. Quantitation of results can be done, for example, by calculating the number of spot forming cells (SFC) per number of cells added into the well.

REPRODUCIBILITY DATA

Peripheral blood mononuclear cells ($1 \times 10^6/\text{mL}$) were stimulated with $1 \mu\text{g/mL}$ of lipopolysaccharide (LPS) overnight at 37°C in $5\% \text{CO}_2$ incubator. The sample was assayed in six wells according to the procedure and analyzed with a dissection microscope.

Well	Number of Spots Counted
1	27
2	30
3	34
4	31
5	37
6	35

TROUBLESHOOTING GUIDE

Observation	Problem	Corrective Action
Following the incubation with BCIP/NBT chromogen and rinsing the microplate with deionized water, the dark-blue background color of filter membrane attenuates visualization and quantitation of spots.	Wet membrane	Microplates cannot be analyzed accurately until PVDF filter membranes are completely dry. Wait until membrane becomes dry, usually 15 - 30 minutes at 37° C or 60 - 90 minutes at room temperature.
The number of spots in the wells that contained the cells is high but their contrast as well as intensity of staining in the Positive Control wells is low.	Underdevelopment - perhaps the result of using Streptavidin-AP and/or BCIP/NBT solutions that have not been brought to room temperature	Warm the reagents to room temperature before adding to the wells.
The number of spots in the wells that contained cells is lower than expected whereas Positive Control wells turned black-blue.	Cell stimulation problem	Ensure that reagents used to stimulate the cytokine release from the cells retained their biological activity. One way to check is to perform immunocytochemistry on fixed cells after stimulation.
	Too few cells added to the wells	Increase the number of cells added per well.
Following incubation with BCIP/NBT and drying the microplate, the density of the spots makes it difficult to quantify them.	Too many cells were added to the wells	Make dilutions of cells (<i>i.e.</i> , 1×10^6 , 5×10^5 , 1×10^5 , 5×10^4 , 1×10^4 cells per well) to determine the optimal number of cells that will result in formation of distinct spots.

REFERENCES

1. Schoenhaut, D.S. *et al.* (1992) *J. Immunol.* **148**:3433.
2. Stern, A.S. *et al.* (1990) *Proc. Natl. Acad. Sci. USA* **87**:6808.
3. Hamza, T. *et al.* (2010) *Int. J. Mol. Sci.* **11**:789.
4. Brombacher, F. *et al.* (2003) *Trends Immunol.* **24**:207.
5. Trinchieri, G. (2003) *Nat. Rev. Immunol.* **3**:133.
6. Gearing, D.P. and D. Cosman (1991) *Cell* **66**:9.
7. Gubler, U. *et al.* (1991) *Proc. Natl. Acad. Sci. USA* **88**:4143.
8. Wolf, S.F. *et al.* (1991) *J. Immunol.* **146**:3074.
9. Verma, N.D. *et al.* (2004) SwissProt Accession #:Q9R103.
10. Khalife, J. *et al.* (1998) *Eur. Cytokine Netw.* **9**:69.
11. Gee, K. *et al.* (2009) *Inflamm. Allergy Drug Targets* **8**:40.
12. Fan, X. *et al.* (1996) *Biochem. Biophys. Res. Commun.* **225**:1063.
13. Kato, T. *et al.* (1997) *Cell. Immunol.* **181**:59.
14. Blotta, M.H. *et al.* (1997) *J. Immunol.* **158**:5589.
15. Kang, K. *et al.* (1996) *J. Immunol.* **156**:1402.
16. Romani, L. *et al.* (1997) *J. Immunol.* **158**:5349.
17. Yawalkar, N. *et al.* (1996) *J. Invest. Dermatol.* **106**:80.
18. Krug, A. *et al.* (2001) *Eur. J. Immunol.* **31**:3026.
19. Shortman, K. and W. Heath (2010) *Immunol. Rev.* **234**:18.
20. Schultze, J.L. *et al.* (1999) *J. Exp. Med.* **189**:1.
21. Chua, A.O. *et al.* (1994) *J. Immunol.* **153**:128.
22. Presky, D.H. *et al.* (1996) *Proc. Natl. Acad. Sci. USA* **93**:14002.
23. Heinzl, F.P. *et al.* (1997) *J. Immunol.* **153**:4381.
24. Sieve, A.N. *et al.* (2010) *Eur. J. Immunol.* **40**:2236.
25. Jana, M. *et al.* (2009) *Glia* **57**:1553.
26. Novelli, F. and J.L. Casanova (2004) *Cytokine Growth Factor Rev.* **15**:367.
27. Sugaya, M. *et al.* (1999) *J. Invest. Dermatol.* **113**:350.
28. Tominaga, K. *et al.* (2000) *Int. Immunol.* **12**:151.
29. Pudda, P. *et al.* (1997) *J. Immunol.* **159**:3490.
30. Collison, L.W. and D. Vignali (2008) *Immunol. Rev.* **226**:248.
31. Czerkinsky, C.C. *et al.* (1983) *J. Immunol. Methods* **65**:109.
32. Sedgwick, J.D. and P.G. Holt (1983) *J. Immunol. Methods* **57**:301.
33. Czerkinsky, C.C. *et al.* (1984) *J. Immunol. Methods* **72**:489.
34. Helms, T. *et al.* (2000) *J. Immunol.* **164**:3723.

ASSAY RECORD TEMPLATE

This template may be used as a record of samples and controls run in an assay.

1								
2								
3								
4								
5								
6								
7								
8								
9								
10								
11								
12								
	A	B	C	D	E	F	G	H

© 2012 R&D Systems, Inc.